0.32
-0.0161(-4.81%)
Currency In USD
| Previous Close | 0.34 |
| Open | 0.33 |
| Day High | 0.34 |
| Day Low | 0.31 |
| 52-Week High | 3.5 |
| 52-Week Low | 0.26 |
| Volume | 1.9M |
| Average Volume | 3.09M |
| Market Cap | 39.74M |
| PE | -0.57 |
| EPS | -0.56 |
| Moving Average 50 Days | 0.4 |
| Moving Average 200 Days | 1.32 |
| Change | -0.02 |
If you invested $1000 in Mersana Therapeutics, Inc. (MRSN) since IPO date, it would be worth $22.78 as of May 10, 2025 at a share price of $0.319. Whereas If you bought $1000 worth of Mersana Therapeutics, Inc. (MRSN) shares 5 years ago, it would be worth $32.84 as of May 10, 2025 at a share price of $0.319.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer
GlobeNewswire Inc.
May 06, 2025 11:00 AM GMT
Cost-saving initiatives expected to extend company’s cash runway and support current operating plan commitments into mid-2026 Company to host conference call at 8:00 a.m. ET on May 15 to discuss business updates and first quarter 2025 financial resul
Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting
GlobeNewswire Inc.
Apr 23, 2025 2:12 PM GMT
CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in area
Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress
GlobeNewswire Inc.
Apr 01, 2025 12:01 PM GMT
CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in area